Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 2,615 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Quality of life assessment Clear all
Completed Phase 1Phase 2 Interventional Results available

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

NCT02273362
View directory record Official record
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
6
States / cities
Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 18, 2026, 9:36 AM EDT
Not listed No phase listed Observational

Patient Reported Outcome Instruments in Sarcoidosis

NCT04342403
View directory record Official record
Conditions
Sarcoidosis
Interventions
Quality of Life
Diagnostic Test
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 18, 2026, 9:36 AM EDT
Completed No phase listed Observational

Comparison of Quality of Life in Patients Undergoing More Intensive Versus Less Intensive Chemotherapy and Radiation Preceding a Bone Marrow Transplant

NCT00004994
View directory record Official record
Conditions
Bone Marrow Transplantation
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 9:36 AM EDT
Active, not recruiting Not applicable Interventional

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

NCT02698254
View directory record Official record
Conditions
Recurrent Brain Neoplasm
Interventions
Bevacizumab, Quality-of-Life Assessment, Radiation Therapy
Biological · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Early Phase 1 Interventional Results available

Muscadine Grape Extract to Improve Fatigue

NCT04495751
View directory record Official record
Conditions
Fatigue
Interventions
Muscadine grape extract, Placebo, Quality of Life Assessment, Questionnaires, Participant Feedback
Dietary Supplement · Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 18, 2026, 9:36 AM EDT
Terminated Phase 1 Interventional

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

NCT02134886
View directory record Official record
Conditions
HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Not applicable Interventional

Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients

NCT03402256
View directory record Official record
Conditions
Alcoholic Liver Disease
Interventions
Text Message
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 18, 2026, 9:36 AM EDT
Withdrawn No phase listed Observational

Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm

NCT02261051
View directory record Official record
Conditions
Cancer, Advanced Cancer
Interventions
Standard of care
Other
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 18, 2026, 9:36 AM EDT
Enrolling by invitation Phase 2 Interventional

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

NCT07393373
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Infigratinib
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 18 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 18, 2026, 9:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Pandemic Induced Stress and Symptoms

NCT06036251
View directory record Official record
Conditions
Stress Reaction, Stress, Emotional, Stress, COVID-19 Pandemic
Interventions
Questionnaires
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Results available

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

NCT03012672
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm
Interventions
Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 18, 2026, 9:36 AM EDT
Not yet recruiting Not applicable Interventional

"F!reF!ghterF!t": Lifestyle Coaching Interventions for Obese Firefighters (FireFit)

NCT06890975
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions
Interventions
Lifestyle Coaching
Behavioral
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sommerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Not applicable Interventional Results available

mHealth for Young Adult Cancer Survivors

NCT05905250
View directory record Official record
Conditions
Survivorship, Cancer, Psychological Well-Being
Interventions
an empirically supported protocol, further refined with evidence-based strategies, Health education
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 39 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 18, 2026, 9:36 AM EDT
Recruiting Not applicable Interventional

Evaluation of a Mobile App Program for Coping With Cancer

NCT06923501
View directory record Official record
Conditions
Cancer
Interventions
Tools for Coping with Cancer Calm Health mobile app program
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Early Phase 1 Interventional

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

NCT02646319
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Malignant Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Solid Neoplasm, Stage III Bladder Cancer, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Breast Cancer, Stage IIIC Ovarian Cancer, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IVA Bladder Cancer, Stage IVA Cervical Cancer, Stage IVB Bladder Cancer, Stage IVB Cervical Cancer
Interventions
Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Phase 3 Interventional

Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite

NCT00031707
View directory record Official record
Conditions
Anorexia, Cachexia
Interventions
eicosapentaenoic acid, megestrol acetate, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
22
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 18, 2026, 9:36 AM EDT
Active, not recruiting Phase 2 Interventional

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

NCT02007044
View directory record Official record
Conditions
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Quality-of-Life Assessment, Questionnaire Administration, Rituximab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Not applicable Interventional

Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00823732
View directory record Official record
Conditions
Lung Cancer
Interventions
educational intervention, medical chart review, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment, management of therapy complications, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management

NCT02199236
View directory record Official record
Conditions
Rectal or Anal Cancer
Interventions
endorectal brachytherapy, concurrent capecitabine or 5-FU, Questionnaires
Radiation · Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Results available

Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis

NCT02743364
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Simvastatin
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 18, 2026, 9:36 AM EDT
Active, not recruiting No phase listed Observational

Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies

NCT01115777
View directory record Official record
Conditions
Brain Tumors, Non-CNS Malignancies
Interventions
Quality of Life surveys completed at specified timepoints
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years to 25 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Phase 3 Interventional

Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

NCT00005036
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
irinotecan hydrochloride, oxaliplatin, leucovorin calcium, fluorouracil, quality-of-life assessment
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 18, 2026, 9:36 AM EDT
Enrolling by invitation Not applicable Interventional

Multidisciplinary Ventricular Assist Device Clinic

NCT05388019
View directory record Official record
Conditions
Heart Failure
Interventions
Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires), Caregiver Self-Assessment
Other · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 18, 2026, 9:36 AM EDT
Completed Not applicable Interventional

Intensive Preoperative Ostomy Education for the Radical Cystectomy Patient

NCT03462667
View directory record Official record
Conditions
Stoma Ileostomy
Interventions
Stoma Boot Camp, Standard of Care
Behavioral · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 18, 2026, 9:36 AM EDT